Novartis (NOVN): price, chart and what’s happening
If you had bought $10 of Novartis every day since November 2021, you would have put in $18,260 and it would be worth $29,410 today (+61.1%). Change the amount, frequency or start date and compare with other assets.
Key numbers · NOVN
In plain words
Novartis (NOVN) is a company in the Healthcare sector, based in Switzerland. The company is worth $285.41 B on the stock market. Revenue over the last year was $57.36 B (+4.70% vs the year before). It is profitable: out of every $100 of revenue, $17.49 is left as net profit. The share costs about 31 years of the company’s earnings (P/E). The price is 6.16% below its 52-week high and 29.3% above its 52-week low. It pays a dividend of about 2.88% of the share price a year. 22 analysts on average rate it “hold” with a price target of $152.55 (+0.08% from today).
Data: Yahoo Finance, updated 2026-11-20. Prices in USD at the current rate. Analyst ratings are opinions, not guarantees. Not investment advice.
What is Novartis (NOVN)?
Novartis is a Basel-based maker of prescription medicines — from the breast-cancer drug Kisqali to the heart pill Entresto — and one of the two giants, with Roche, that make Switzerland's stock market a pharma market.
How it makes money
Novartis researches new medicines, wins patents and sells the drugs to hospitals, insurers and health systems worldwide. In 2025 it sold $54.5 billion (+8%) and earned $14.0 billion in net profit, keeping about 40 cents of every dollar of sales as core operating profit. Its biggest products are Entresto (heart failure, $7.7 billion in 2025), Cosentyx (psoriasis and arthritis, $6.7 billion), Kisqali ($4.8 billion, +58%) and Kesimpta (multiple sclerosis, $4.4 billion).
The company was born in 1996 from the merger of Ciba-Geigy and Sandoz. It later spun off its eye-care unit Alcon (2019) and its generics arm Sandoz (2023), so today it is a pure "innovative medicines" company.
Why it matters
Novartis is one of the heaviest stocks in the Swiss SMI index and a classic dividend payer: for 2025 it proposed CHF 3.70 per share, its 29th increase in a row since it was created. One surprising fact: in the third quarter of 2026 Entresto sales fell 38% after US generics arrived — yet total sales still grew 4%, carried by Kisqali (+37%) and the cholesterol shot Leqvio (+63%).
Key numbers
- Price today: $152.42
- $10 a day for 5 years: $29,410 from $18,260 invested (+61.1%)
- $10 a day for 10 years: $78,457 from $36,520 invested (+115%)
See more of the market on the Swiss stocks page.
Main risks
Patents expire: every blockbuster eventually faces cheaper copies, and new drugs must replace the lost sales. Research is risky — in Q3 2026 Novartis wrote down $1.9 billion on one experimental drug. US drug-price pressure and tariffs hit all big pharma. Prices on our site are in US dollars, so the Swiss franc also moves the return. Buying a fixed amount regularly smooths price swings but does not remove the risk.
Not investment advice.
Sources
Novartis (NOVN): returns by month
Portfolio value over time
Technical analysis · NOVN
News · NOVN
Fundamentals · NOVN
$10 a day in Novartis: results by period
| Period | Invested | Now | Result |
|---|---|---|---|
| 1 year | $3,650 | $3,712 | +1.71% |
| 3 years | $10,960 | $14,485 | +32.2% |
| 5 years | $18,260 | $29,410 | +61.1% |
| 10 years | $36,520 | $78,457 | +115% |
| Since Jan 2000 | $98,210 | $517,196 | +427% |
FAQ
What does Novartis do?
Novartis (NOVN) is a company in the Healthcare sector, based in Switzerland. The company is worth $285.41 B on the stock market. Revenue over the last year was $57.36 B (+4.70% vs the year before).
What would $1,000 invested in Novartis 5 years ago be worth today?
A one-time $1,000 investment in Novartis 5 years ago would be worth $2,444 today (+144%).
Does Novartis pay a dividend?
It pays a dividend of about 2.88% of the share price a year.
What is Novartis’s P/E?
The share costs about 30.6 years of the company’s earnings (P/E).
What do analysts say about Novartis?
22 analysts on average rate it “hold” with a price target of $152.55 (+0.08% from today). Analyst ratings are opinions, not guarantees. Not investment advice.
How much would I have if I invested $10 a day in Novartis since November 2021?
You would have invested $18,260, and as of November 2026 it would be worth $29,410 (+61.1%). Based on monthly closing prices, before fees and taxes.
Which was better to buy daily over the last 5 years: Novartis or Bitcoin?
$10 a day over the last 5 years would have returned +61.1% for Novartis and +43.3% for Bitcoin. Past performance does not guarantee future results.
Is it worth buying Novartis (NOVN) every day?
Historically, buying Novartis with $10 a day returned +1.71% over the last year and +61.1% over 5 years. Use the calculator above to test other amounts, weekly or monthly purchases and other start dates.
What is DCA (dollar-cost averaging)?
DCA means buying an asset for the same amount at regular intervals, whatever the price. You buy more when it is cheap and less when it is expensive, which smooths volatility and removes the need to time the market.
Similar companies
| Name | Price | 24h |
|---|---|---|
| $175.41 | −1.87% | |
| $132.81 | −3.61% | |
| $438.82 | −1.14% | |
| $166.53 | −1.45% | |
| $283.54 | −0.86% | |
| $27.54 | −1.85% | |
| $267.14 | −2.04% | |
| $58.34 | −2.05% |
Similar assets: Stock
| Name | Price | 24h |
|---|---|---|
| NvidiaNVDA | $145.98 | −3.30% |
| AppleAAPL | $349.21 | −0.92% |
| MicrosoftMSFT | $498.30 | −1.78% |
| Alphabet (Google)GOOG | $271.02 | −2.93% |
| AmazonAMZN | $257.37 | −3.87% |
| MetaMETA | $596.22 | −3.27% |
| TeslaTSLA | $374.41 | −2.43% |
| NetflixNFLX | $58.46 | −2.27% |
| BroadcomAVGO | $346.65 | −2.09% |
| TSMCTSM | $352.09 | −2.90% |
</> Embed · Embed this calculator on your site
This Novartis (NOVN) DCA calculator shows how much you would have made by investing in Novartis regularly — every day, week or month — instead of all at once. It is a free investment calculator for dollar-cost averaging into crypto, stocks and gold.